# Chiara Baldini

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 166 papers | 5,910 citations | 76294 40 h-index | 88593 70 g-index |
| 168 all docs | 168 docs citations | 168 times ranked | 6062 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | SjÃ¶gren syndrome. Nature Reviews Disease Primers, 2016, 2, 16047. | 18.1 | 511 |
| 2 | Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. European Journal of Internal Medicine, 2015, 26, 545-553. | 1.0 | 371 |
| 3 | Anti-Sm and anti-RNP antibodies. Autoimmunity, 2005, 38, 47-54. | 1.2 | 201 |
| 4 | Primary SjÃ¶grenâ€™s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology, 2014, 53, 839-844. | 0.9 | 185 |
| 5 | SjÃ¶gren's syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in SjÃ¶gren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis and Rheumatism, 2007, 56, 2223-2231. | 6.7 | 167 |
| 6 | Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nature Communications, 2019, 10, 5120. | 5.8 | 160 |
| 7 | Proteome analysis of whole saliva: A new tool for rheumatic diseases â€“ the example of SjÃ¶gren's syndrome. Proteomics, 2007, 7, 1634-1643. | 1.3 | 134 |
| 8 | Influence of geolocation and ethnicity on the phenotypic expression of primary SjÃ¶gren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data SjÃ¶gren Project Consortium. Annals of the Rheumatic Diseases, 2017, 76, 1042-1050. | 0.5 | 132 |
| 9 | Biomarkers of lymphoma in SjÃ¶grenâ€™s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: Results of a multicenter study. Journal of Autoimmunity, 2014, 51, 75-80. | 3.0 | 126 |
| 10 | Classification criteria for Sjogrenâ€™s syndrome: A critical review. Journal of Autoimmunity, 2012, 39, 9-14. | 3.0 | 122 |
| 11 | Is salivary gland ultrasonography a useful tool in SjÃ¶grenâ€™s syndrome? A systematic review. Rheumatology, 2016, 55, 789-800. | 0.9 | 120 |
| 12 | Early diagnosis of primary SjÃ¶grenâ€™s syndrome: EULAR-SS task force clinical recommendations. Expert Review of Clinical Immunology, 2016, 12, 137-156. | 1.3 | 118 |
| 13 | Cardiovascular disease risk burden in primary SjÃ¶gren's syndrome: results of a populationâ€based multicentre cohort study. Journal of Internal Medicine, 2015, 278, 185-192. | 2.7 | 110 |
| 14 | International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2 | 2.5 | 107 |
| 15 | The diagnosis and classification of mixed connective tissue disease. Journal of Autoimmunity, 2014, 48-49, 46-49. | 3.0 | 101 |
| 16 | Proteomic analysis of saliva: a unique tool to distinguish primary SjÃ¶gren's syndrome from secondary SjÃ¶gren's syndrome and other sicca syndromes. Arthritis Research and Therapy, 2011, 13, R194. | 1.6 | 97 |
| 17 | Undifferentiated connective tissue diseases (UCTD). Autoimmunity Reviews, 2006, 6, 1-4. | 2.5 | 96 |
| 18 | Salivary gland ultrasonography: a highly specific tool for the early diagnosis of primary SjÃ¶grenâ€™s syndrome. Arthritis Research and Therapy, 2015, 17, 146. | 1.6 | 94 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Salivary gland ultrasound abnormalities in primary SjÃ¶grenâ€™s syndrome: consensual US-SG core items definition and reliability. RMD Open, 2017, 3, e000364. | 1.8 | 87 |
| 20 | Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies SjÃ¶grenâ€™s syndrome with ectopic germinal centres and MALT lymphoma. Annals of the Rheumatic Diseases, 2020, 79, 1588-1599. | 0.5 | 83 |
| 21 | Rhupus syndrome: Assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmunity Reviews, 2013, 12, 537-541. | 2.5 | 82 |
| 22 | Anti-SSA/SSB-negative SjÃ¶gren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmunity Reviews, 2015, 14, 1019-1022. | 2.5 | 80 |
| 23 | Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. Arthritis and Rheumatology, 2022, 74, 295-306. | 2.9 | 78 |
| 24 | Clinical Manifestations and Treatment of Churg-Strauss Syndrome. Rheumatic Disease Clinics of North America, 2010, 36, 527-543. | 0.8 | 76 |
| 25 | The P2X<sub>7</sub> receptorâ€“inflammasome complex has a role in modulating the inflammatory response in primary <scp>S</scp>jÃ¶gren's syndrome. Journal of Internal Medicine, 2013, 274, 480-489. | 2.7 | 74 |
| 26 | COVID-19: the new challenge for rheumatologists. Clinical and Experimental Rheumatology, 2020, 38, 175-180. | 0.4 | 69 |
| 27 | Characterization of a new regulatory CD4+ T cell subset in primary Sjogren's syndrome. Rheumatology, 2013, 52, 1387-1396. | 0.9 | 63 |
| 28 | A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary SjÃ¶grenâ€™s syndrome. Lupus, 2015, 24, 315-320. | 0.8 | 63 |
| 29 | The JAKâ€“STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. European Heart Journal, 2021, 42, 4389-4400. | 1.0 | 61 |
| 30 | Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary SjÓ§gren's syndrome: A systematic review from the Italian Society of Rheumatology. Autoimmunity Reviews, 2020, 19, 102447. | 2.5 | 59 |
| 31 | Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?. Rheumatology, 2005, 44, 1074-1075. | 0.9 | 56 |
| 32 | Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. Arthritis Research and Therapy, 2015, 17, 277. | 1.6 | 55 |
| 33 | Epidemiological profile and northâ€“south gradient driving baseline systemic involvement of primary SjÃ¶grenâ€™s syndrome. Rheumatology, 2020, 59, 2350-2359. | 0.9 | 54 |
| 34 | Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of SjÃ¶grenâ€™s syndrome. RMD Open, 2019, 5, e001064. | 1.8 | 53 |
| 35 | Proteomic analysis of the saliva: A clue for understanding primary from secondary SjÃ¶gren's syndrome?. Autoimmunity Reviews, 2008, 7, 185-191. | 2.5 | 52 |
| 36 | Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary SjÃ¶gren's syndrome: results of a large multicentre study. Scandinavian Journal of Rheumatology, 2015, 44, 36-41. | 0.6 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | A Clinical Prediction Rule for Lymphoma Development in Primary SjÃ¶grenâ€™s Syndrome. Journal of Rheumatology, 2012, 39, 804-808. | 1.0 | 48 |
| 38 | Biomarkers for SjÃ¶grenâ€™s syndrome. Biomarkers in Medicine, 2018, 12, 275-286. | 0.6 | 47 |
| 39 | Is GRP78/BiP a potential salivary biomarker in patients with rheumatoid arthritis?. Proteomics - Clinical Applications, 2010, 4, 315-324. | 0.8 | 46 |
| 40 | Primary SjÃ¶grenâ€™s Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development. Frontiers in Immunology, 2020, 11, 594096. | 2.2 | 45 |
| 41 | Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis. Journal of Rheumatology, 2007, 34, 2063-9. | 1.0 | 40 |
| 42 | Detection of potential markers of primary fibromyalgia syndrome in human saliva. Proteomics - Clinical Applications, 2009, 3, 1296-1304. | 0.8 | 39 |
| 43 | One year in review 2017: primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2017, 35, 179-191. | 0.4 | 38 |
| 44 | How immunological profile drives clinical phenotype of primary SjÃ¶gren's syndrome at diagnosis: analysis of 10,500 patients (SjÃ¶gren Big Data Project). Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 102-112. | 0.4 | 37 |
| 45 | Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2. Frontiers in Oncology, 2020, 10, 1428. | 1.3 | 36 |
| 46 | The CoV-2 outbreak: how hematologists could help to fight Covid-19. Pharmacological Research, 2020, 157, 104866. | 3.1 | 36 |
| 47 | One year in review 2021: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 3-13. | 0.4 | 35 |
| 48 | Proteomic diagnosis of SjÃ¶grenâ€™s syndrome. Expert Review of Proteomics, 2007, 4, 757-767. | 1.3 | 34 |
| 49 | SjÃ¶grenâ€™s syndrome: state of the art on clinical practice guidelines. RMD Open, 2018, 4, e000789. | 1.8 | 34 |
| 50 | Cryoglobulinemia in SjÃ¶gren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. Journal of Rheumatology, 2017, 44, 1179-1183. | 1.0 | 33 |
| 51 | Overlap of ACA-positive systemic sclerosis and SjÃ¶gren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clinical and Experimental Rheumatology, 2013, 31, 272-80. | 0.4 | 33 |
| 52 | Outcome of Pregnancy in Italian Patients with Primary SjÃ¶gren Syndrome. Journal of Rheumatology, 2013, 40, 1143-1147. | 1.0 | 32 |
| 53 | Comorbidities (excluding lymphoma) in SjÃ¶grenâ€™s syndrome. Rheumatology, 2021, 60, 2075-2084. | 0.9 | 30 |
| 54 | One year in review 2015: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2015, 33, 259-71. | 0.4 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity. Clinical Rheumatology, 2013, 32, 1071-1073. | 1.0 | 29 |
| 56 | Major Salivary Gland Ultrasonography in the Diagnosis of SjÃ¶grenâ€™s Syndrome. Rheumatic Disease Clinics of North America, 2016, 42, 501-517. | 0.8 | 28 |
| 57 | Vitamin D in â€œearlyâ€•primary SjÃ¶grenâ€™s syndrome: does it play a role in influencing disease phenotypes?. Rheumatology International, 2014, 34, 1159-1164. | 1.5 | 27 |
| 58 | Myositis in primary SjÃ¶gren's syndrome: data from a multicentre cohort. Clinical and Experimental Rheumatology, 2015, 33, 457-64. | 0.4 | 27 |
| 59 | Difference in clinical presentation between women and men in incident primary SjÃ¶grenâ€™s syndrome. Biology of Sex Differences, 2017, 8, 16. | 1.8 | 26 |
| 60 | The Association of SjÃ¶gren Syndrome and Autoimmune Thyroid Disorders. Frontiers in Endocrinology, 2018, 9, 121. | 1.5 | 26 |
| 61 | SjÃ¶grenâ€™s Syndrome: The Clinical Spectrum of Male Patients. Journal of Clinical Medicine, 2020, 9, 2620. | 1.0 | 26 |
| 62 | One year in review 2016: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2016, 34, 161-71. | 0.4 | 26 |
| 63 | Ultrasonography of major salivary glands: a highly specific tool for distinguishing primary SjÃ¶grenâ€™s syndrome from undifferentiated connective tissue diseases. Rheumatology, 2015, 54, kev253. | 0.9 | 25 |
| 64 | Cystatin Sâ€”a candidate biomarker for severity of submandibular gland involvement in SjÃ¶grenâ€™s syndrome. Rheumatology, 2017, 56, 1031-1038. | 0.9 | 25 |
| 65 | Saliva as an ideal milieu for emerging diagnostic approaches in primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2012, 30, 785-90. | 0.4 | 25 |
| 66 | Focus on audiologic impairment in eosinophilic granulomatosis with polyangiitis. Laryngoscope, 2016, 126, 2792-2797. | 1.1 | 24 |
| 67 | Focus on the Involvement of the Nose and Paranasal Sinuses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Nasal Cytology Reveals Infiltration of Eosinophils as a Very Common Feature. International Archives of Allergy and Immunology, 2018, 175, 61-69. | 0.9 | 24 |
| 68 | Childhood-onset of primary SjÃ¶grenâ€™s syndrome: phenotypic characterization at diagnosis of 158 children. Rheumatology, 2021, 60, 4558-4567. | 0.9 | 24 |
| 69 | A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. Journal of Autoimmunity, 2021, 121, 102648. | 3.0 | 24 |
| 70 | Correspondence between salivary proteomic pattern and clinical course in primary SjÃ¶gren syndrome and non-Hodgkin's lymphoma: a case report. Journal of Translational Medicine, 2011, 9, 188. | 1.8 | 22 |
| 71 | Updates on SjÃ¶grenâ€™s syndrome: from proteomics to protein biomarkers. Expert Review of Proteomics, 2017, 14, 491-498. | 1.3 | 22 |
| 72 | Phenotyping multiple subsets in SjÃ¶grenâ€™s syndrome: a salivary proteomic SWATH-MS approach towards precision medicine. Clinical Proteomics, 2019, 16, 26. | 1.1 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Asthma Control and Airway Inflammation in Patients with Eosinophilic Granulomatosis with Polyangiitis. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 512-519. | 2.0 | 21 |
| 74 | Celiac Disease Prevalence Is Increased in Primary SjÃ¶grenâ€™s Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. Journal of Clinical Medicine, 2019, 8, 540. | 1.0 | 20 |
| 75 | Association of psoriasin (S100A7) with clinical manifestations of systemic sclerosis: is its presence in whole saliva a potential predictor of pulmonary involvement?. Journal of Rheumatology, 2008, 35, 1820-4. | 1.0 | 19 |
| 76 | Sicca/SjÃ¶gren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 114-122. | 0.4 | 19 |
| 77 | Minor salivary gland biopsy and SjÃ¶gren's syndrome: comparative analysis of biopsies among different Italian rheumatologic centers. Clinical and Experimental Rheumatology, 2012, 30, 929-33. | 0.4 | 16 |
| 78 | One year in review 2019: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 3-15. | 0.4 | 16 |
| 79 | Fibronectin gene polymorphisms are associated with the development of B-cell lymphoma in type II mixed cryoglobulinemia. Annals of the Rheumatic Diseases, 2008, 67, 80-83. | 0.5 | 15 |
| 80 | SARS-CoV-2 infection in patients with primary SjÃ¶gren syndrome: characterization and outcomes of 51 patients. Rheumatology, 2021, 60, 2946-2957. | 0.9 | 15 |
| 81 | Unraveling Human AQP5-PIP Molecular Interaction and Effect on AQP5 Salivary Glands Localization in SS Patients. Cells, 2021, 10, 2108. | 1.8 | 15 |
| 82 | COVID-19: the new challenge for rheumatologists. First update. Clinical and Experimental Rheumatology, 2020, 38, 373-382. | 0.4 | 15 |
| 83 | Treatment of chronic hepatitis C infection with cryoglobulinemia. Current Opinion in Rheumatology, 2002, 14, 231-237. | 2.0 | 14 |
| 84 | LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. Expert Opinion on Pharmacotherapy, 2007, 8, 873-879. | 0.9 | 14 |
| 85 | TNF-alpha inhibitors in Systemic Lupus Erythematosus. A case report and a systematic literature review. Modern Rheumatology, 2015, 25, 642-645. | 0.9 | 14 |
| 86 | The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia. Frontiers in Oncology, 2019, 9, 532. | 1.3 | 14 |
| 87 | Muscular vasculitis confined to lower limbs: description of two case reports and a review of the literature. Rheumatology International, 2017, 37, 2115-2121. | 1.5 | 13 |
| 88 | Characterization of Extracellular Vesicle Cargo in SjÃ¶grenâ€™s Syndrome through a SWATH-MS Proteomics Approach. International Journal of Molecular Sciences, 2021, 22, 4864. | 1.8 | 13 |
| 89 | Ezrin Is a Novel Protein Partner of Aquaporin-5 in Human Salivary Glands and Shows Altered Expression and Cellular Localization in SjÃ¶grenâ€™s Syndrome. International Journal of Molecular Sciences, 2021, 22, 9213. | 1.8 | 13 |
| 90 | Ultra-high frequency ultrasound (UHFUS) applications in Sjogren syndrome: narrative review and current concepts. Gland Surgery, 2020, 9, 2248-2259. | 0.5 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Emerging trends in SjÃ¶gren's syndrome: basic and translational research. Clinical and Experimental Rheumatology, 2012, 30, 779-84. | 0.4 | 13 |
| 92 | Analysis of the evolution of UCTD to defined CTD after a long term follow-up. Clinical and Experimental Rheumatology, 2013, 31, 471. | 0.4 | 13 |
| 93 | Peripheral Nervous System Involvement in SjÃ¶grenâ€™s Syndrome: Analysis of a Cohort From the Italian Research Group on SjÃ¶grenâ€™s Syndrome. Frontiers in Immunology, 2021, 12, 615656. | 2.2 | 12 |
| 94 | Imaging in primary SjÃ¶gren's syndrome: the 'obsolete and the new'. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 215-221. | 0.4 | 12 |
| 95 | Advances in salivary gland ultrasonography in primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 114, 159-164. | 0.4 | 12 |
| 96 | Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology, 2022, 62, 243-255. | 0.9 | 12 |
| 97 | Influence of the age at diagnosis in the disease expression of primary SjÃ¶gren syndrome. Analysis of 12,753 patients from the SjÃ¶gren Big Data Consortium. Clinical and Experimental Rheumatology, 2021, 39, 166-174. | 0.4 | 12 |
| 98 | Occurrence of organ-specific and systemic autoimmune diseases among the first- and second-degree relatives of Caucasian patients with connective tissue diseases: report of data obtained through direct patient interviews. Clinical Rheumatology, 2008, 27, 1045-1048. | 1.0 | 11 |
| 99 | In vivo confocal scanning laser microscopy in patients with primary SjÃ¶gren's syndrome: A monocentric experience. Modern Rheumatology, 2015, 25, 585-589. | 0.9 | 11 |
| 100 | Ultraâ€high frequency ultrasonography (UHFUS)â€guided minor salivary gland biopsy: A promising procedure to optimize labial salivary gland biopsy in SjÃ¶grenâ€™s syndrome. Journal of Oral Pathology and Medicine, 2021, 50, 485-491. | 1.4 | 10 |
| 101 | Large- and small-vessel vasculitis: a critical digest of the 2010-2011 literature. Clinical and Experimental Rheumatology, 2012, 30, S130-8. | 0.4 | 10 |
| 102 | One year in review 2018: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 14-26. | 0.4 | 10 |
| 103 | Development of de novo major involvement during follow-up in BehÃ§etâ€™s syndrome. Clinical Rheumatology, 2016, 35, 247-250. | 1.0 | 9 |
| 104 | One year in review: systemic vasculitis. Clinical and Experimental Rheumatology, 2016, 34, S1-6. | 0.4 | 9 |
| 105 | One year in review 2018: systemic vasculitis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 12-32. | 0.4 | 9 |
| 106 | One year in review 2021: systemic vasculitis. Clinical and Experimental Rheumatology, 2021, 39, 3-12. | 0.4 | 9 |
| 107 | MicroRNA-mediated Regulation of Mucin-type O-glycosylation Pathway: A Putative Mechanism of Salivary Gland Dysfunction in SjÃ¶gren Syndrome. Journal of Rheumatology, 2019, 46, 1485-1494. | 1.0 | 8 |
| 108 | Salivary extracellular vesicles versus whole saliva: new perspectives for the identification of proteomic biomarkers in SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 240-248. | 0.4 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | One year in review 2020: pathogenesis of primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 3-9. | 0.4 | 8 |
| 110 | Myeloid neoplasms and autoimmune diseases: markers of association. Clinical and Experimental Rheumatology, 2022, 40, 49-55. | 0.4 | 8 |
| 111 | Combined seronegativity in SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 80-84. | 0.4 | 8 |
| 112 | A proposal of simple calculation (ERI calculator) to predict the early response to TNF-Î± blockers therapy in rheumatoid arthritis. Rheumatology International, 2012, 32, 349-356. | 1.5 | 7 |
| 113 | Rate of serious infections in BehÃ§etâ€™s disease patients receiving biologic therapies: a prospective observational study. Clinical Rheumatology, 2013, 32, 1547-1548. | 1.0 | 7 |
| 114 | Addressing the clinical unmet needs in primary SjÃ¶grenâ€™s Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts. Computational and Structural Biotechnology Journal, 2022, 20, 471-484. | 1.9 | 7 |
| 115 | The classification criteria for SjÃ¶gren syndrome: issues for their improvement from the study of a large Italian cohort of patients. Annals of the Rheumatic Diseases, 2014, 73, e35-e35. | 0.5 | 6 |
| 116 | Ocular Surface Disease Index (OSDI): a potential useful instrument for the assessment of vision-targeted health-related quality of life (VT-HRQ) in primary SjÃ¶gren's syndrome (pSS) clinical trials?. Clinical and Experimental Rheumatology, 2012, 30, 812-3. | 0.4 | 6 |
| 117 | One year in review 2016: idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2016, 34, 966-974. | 0.4 | 6 |
| 118 | Artificial neural networks help to identify disease subsets and to predict lymphoma in primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 137-144. | 0.4 | 6 |
| 119 | Systemic manifestations of primary SjÃ¶gren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 97-106. | 0.4 | 6 |
| 120 | Pain in SjÃ¶grenâ€™s syndrome. Reumatismo, 2014, 66, 39-43. | 0.4 | 5 |
| 121 | Systemic vasculitis and the lung. Current Opinion in Rheumatology, 2017, 29, 45-50. | 2.0 | 5 |
| 122 | The use of digital image analysis in the histological assessment of SjÃ¶gren's syndrome salivary glands improves inter-rater agreement and facilitates multicentre data harmonisation. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 180-188. | 0.4 | 5 |
| 123 | COVID-19: the new challenge for rheumatologists. One year later. Clinical and Experimental Rheumatology, 2021, 39, 203-213. | 0.4 | 5 |
| 124 | A New Method for the Assessment of Myalgia in Interstitial Lung Disease: Association with Positivity for Myositis-Specific and Myositis-Associated Antibodies. Diagnostics, 2022, 12, 1139. | 1.3 | 5 |
| 125 | Salivary Proteomics Markers for Preclinical SjÃ¶grenâ€™s Syndrome: A Pilot Study. Biomolecules, 2022, 12, 738. | 1.8 | 5 |
| 126 | Rheumatoid factor in SjÃ¶gren's syndrome: The need to target MALT tissue for preventing lymphoma. Arthritis and Rheumatology, 2016, 68, n/a-n/a. | 2.9 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Therapeutic Recommendations for the Management of Older Adult Patients with SjÃ¶grenâ€™s Syndrome. Drugs and Aging, 2021, 38, 265-284. | 1.3 | 4 |
| 128 | One year in review 2019: vasculitis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 3-19. | 0.4 | 4 |
| 129 | Myeloid neoplasms and autoimmune diseases: markers of association. Clinical and Experimental Rheumatology, 2021, , . | 0.4 | 4 |
| 130 | One year in review 2021: SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, , . | 0.4 | 4 |
| 131 | Classification criteria in SjÃ¶grenâ€™s syndrome. Annals of Translational Medicine, 2017, 5, 313-313. | 0.7 | 3 |
| 132 | Fitness for purpose of routinely recorded health data to identify patients with complex diseases: The case of SjÃ¶gren's syndrome. Learning Health Systems, 2020, 4, e10242. | 1.1 | 3 |
| 133 | Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2017, 35, 546-547. | 0.4 | 3 |
| 134 | One year in review 2017: systemic vasculitis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 5-26. | 0.4 | 3 |
| 135 | Application of artificial neural network analysis in the evaluation of cardiovascular risk in primary SjÃ¶gren's syndrome: a novel pathogenetic scenario?. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 133-139. | 0.4 | 3 |
| 136 | Ultra-high frequency ultrasonography of labial glands is a highly sensitive tool for the diagnosis of SjÃ¶gren's syndrome: a preliminary study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 210-215. | 0.4 | 3 |
| 137 | Total area of inflammatory infiltrate and percentage of inflammatory infiltrate identify different clinical-serological subsets of primary SjÃ¶gren's syndrome better than traditional histopathological parameters. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 195-202. | 0.4 | 3 |
| 138 | SjÃ¶gren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. Clinical and Experimental Rheumatology, 2022, 40, 103-112. | 0.4 | 3 |
| 139 | Mucocutaneous Manifestations of Sjogren's Syndrome. Handbook of Systemic Autoimmune Diseases, 2006, 5, 147-160. | 0.1 | 2 |
| 140 | Future prospects for salivary proteomics in rheumatology: the example of eosinophil granulomatosis with polyangiitis. Clinical and Experimental Rheumatology, 2012, 30, 810-1. | 0.4 | 2 |
| 141 | A clinical and histopathological analysis of the anti-centromere antibody positive subset of primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 145-149. | 0.4 | 2 |
| 142 | One year in review 2020: vasculitis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 3-14. | 0.4 | 2 |
| 143 | Systemic phenotype related to primary SjÃ¶gren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 85-94. | 0.4 | 2 |
| 144 | One year in review 2021: systemic vasculitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 3-12. | 0.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Mikulicz's disease: a long-term follow-up case report. Clinical and Experimental Rheumatology, 2012, 30, 596. | 0.4 | 1 |
| 146 | One year in review 2015: idiopathic inflammatory myopathies. Clinical and Experimental Rheumatology, 2015, 33, 593-601. | 0.4 | 1 |
| 147 | Variation in primary SjÃ¶gren's syndrome care among European countries. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 27-28. | 0.4 | 1 |
| 148 | COVID-19: the new challenge for rheumatologists. One year later. Clinical and Experimental Rheumatology, 2021, 39, 203-213. | 0.4 | 1 |
| 149 | Patient-reported experience and health-related quality of life in patients with primary SjÃ¶gren's syndrome in Europe. Clinical and Experimental Rheumatology, 2021, 39, 123-130. | 0.4 | 1 |
| 150 | Systemic vasculitis: one year in review 2022. Clinical and Experimental Rheumatology, 2022, 40, 673-687. | 0.4 | 1 |
| 151 | Occurrence of Hashimoto thyroiditis among the first- and second-degree relatives of systemic lupus erythematosus patients with Hashimoto thyroiditis. Reumatismo, 2013, 65, 203-4. | 0.4 | 0 |
| 152 | SAT0175â€…ULTRA-HIGH-FREQUENCY ULTRASOUND OF LABIAL SALIVARY GLANDS HIGHLY CORRELATES WITH HISTOPATHOLOGY IN PRIMARY SJÃ–GRENâ€™S SYNDROME. , 2019, , . | | 0 |
| 153 | FRI0223â€…EXTRACELLULAR VESICLESAS A SOURCE OF BIOMARKERS IN SJÃ¶GREN SYNDROME: A SWATH-MS PROTEOMIC APPROACH. , 2019, , . | | 0 |
| 154 | SAT0190â€…LYMPHOMA IN PRIMARY SJÃ–GRENâ€™S SYNDROME: A RETROSPECTIVE CLINICAL STUDY WITH PATIENTS FROM THE UPA (UDINE, PISA, ATHENS) GROUP. , 2019, , . | | 0 |
| 155 | THU0259â€…ULTRASOUND OF MAJOR SALIVARY GLANDS IDENTIFIES PATIENTS WITH MORE COMPLEX SALIVARY GLAND HISTOPATHOLOGY BUT NOT MILDER LESIONS. , 2019, , . | | 0 |
| 156 | OP0279â€…A UNIQUE IL-21 SIGNATURE CHARACTERIZES LESIONAL AND CIRCULATING T-FOLLICULAR HELPER CELLS IN SJÃ–GRENâ€™S SYNDROME PATIENTS WITH ECTOPIC GERMINAL CENTRES AND MALT LYMPHOMA. , 2019, , . | | 0 |
| 157 | Unusual concomitant smallâ€•and largeâ€fiber neuropathy related to hypereosinophilic syndrome. Clinical and Experimental Neuroimmunology, 0, , . | 0.5 | 0 |
| 158 | Classification Criteria. , 2011, , 417-428. | | 0 |
| 159 | Classification Criteria of SjÃ¶grenâ€™s Syndrome. Rare Diseases of the Immune System, 2016, , 267-278. | 0.1 | 0 |
| 160 | Significance of anti-La/SSB antibodies in primary SjÃ¶gren's syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsy. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 53-56. | 0.4 | 0 |
| 161 | Validation of thymic stromal lymphopoietin as a biomarker of primary SjÃ¶gren's syndrome and related lymphoproliferation: results in independent cohorts. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 189-194. | 0.4 | 0 |
| 162 | Combined seronegativity in SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2021, , . | 0.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Patient-reported experience and health-related quality of life in patients with primary SjÃ¶gren's syndrome in Europe. Clinical and Experimental Rheumatology, 2021, , . | 0.4 | 0 |
| 164 | Classification Criteria in SjÃ¶grenâ€™s Syndrome. , 2022, , 29-35. | | 0 |
| 165 | Influence of the age at diagnosis in the disease expression of primary SjÃ¶gren syndrome. Analysis of 12,753 patients from the SjÃ¶gren Big Data Consortium.. Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174. | 0.4 | 0 |
| 166 | SjÃ¶gren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. Clinical and Experimental Rheumatology, 2022, , . | 0.4 | 0 |